SYGNIS Boosts Marketing Activities Presenting At Renowned Scientific Conferences In Europe And The U.S.
Madrid, Spain and Heidelberg, Germany, March 02, 2016 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it will present its revolutionary novel multi displacement amplification (MDA) technology TruePrime™ at two upcoming renowned scientific conferences.
23rd Molecular Medicine Tri Conference (Molecular Med TRI-CON),
March 6th – 11th, San Francisco, CA, USA
Attracting over 3,300 drug discovery and development professionals from over 40 countries in 2015, the Tri Conference hosted by the Cambridge Healthtech Institute has grown into a diverse event, focusing on Molecular Medicine, specifically on Discovery, Genomics, Diagnostics and Information Technology. Dr Miguel Viribay, Vice President Sales & Marketing at SYGNIS, will present SYGNIS’ product portfolio at the Main Conference from March 7th to 9th (booth #532) and the TruePrime™ Cell-Free DNA Amplification kit, a new product currently under development in an additional symposium on Circulating Cell-free DNA on March 10th and 11th (booth #14).
More information on this conference can be found at http://www.triconference.com
10th International Symposium on Minimal Residual Cancer: Liquid Biopsy in Cancer Diagnostics and Treatment (ISMRC), March 19th - 21st, Hamburg, Germany
Organized together with the newly established EU IMI (Innovative Medicines Initiative) consortium, CANCER-ID ISMRC is a premier event focusing on the detection, characterization & clinical relevance of Circulating Tumor Cells (CTCs) in solid tumors. The 2016 program will focus on Liquid biopsy including presentations on CTCs and circulating nucleic acids (DNA, miRNA) as well as exosomes. SYGNIS will be represented by Armin Schneider (Senior Vice President Research), Ángel Picher (Associated Director Product Development) and Miguel Viribay (Vice President Sales & Marketing). The Company is currently broadening the TruePrime™ technology to empower researchers and clinicians in cancer research, cancer diagnostics, clinical drug development and patient monitoring to rapidly amplify cell free DNA from plasma and serum with highest sensitivity and reliability. Ángel Picher will present first results of this newly developed product in the poster session 3: Dissemination Biology, Circulating Nucleic Acids & Comparative Studies , on March 20, 2016, at 17:10 CET (Poster number: P113). The poster’s title is: TruePrime™ liquid biopsy: Tuning whole genome amplification towards improving the sensitivity of circulating tumor DNA analysis .
More information on ISMRC can be found at http://ismrc2016.com
About Circulating Cell-free DNA
Circulating cell-free DNA detection is currently one of the hottest topics in oncology. The fact of getting accurate and reliable results in an analysis of circulating tumor DNA in the very early stages of cancer development by non-invasive liquid biopsy opens up new fields of opportunities in both basic cancer research and cancer clinical aspects. Circulating tumor cells (CTCs) in the patient’s blood are responsible for metastases. The molecular characterization of CTCs via liquid biopsy provides a portrait of the specific disease state over time. Liquid biopsy allow for a new type of blood-based tests that have the potential to transfer cancer treatment as they allow for an easy, fast and reliable early detection of cancer and monitoring tumor progression of cancer patients under treatment. Based on the features and benefits of the TruePrime™ technology, SYGNIS is currently developing a perfect tool that significantly simplifies and standardizes amplification of cell-free DNA from liquid biopsies for these kinds of tests.
For further information please contact: SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
+34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
+49 89 210228 30
Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
SYGNIS, headquartered in Germany and Spain, specializes on the development and commercialization of innovative products for DNA amplification and sequencing. Based on its proprietary technologies, SYGNIS has developed a commercial product portfolio addressing key challenges in the fast growing fields of molecular biology and next generation sequencing applications. Key products include the TruePrime™ product line and SensiPhi®, licensed to an industry leading partner, for whole genome DNA amplification and sequencing as well as the SunScript™ Reverse Transcriptase product family to convert genetic information from RNA molecules back to DNA. SYGNIS AG is listed at the German Stock Exchange in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).
23rd Molecular Medicine Tri Conference (Molecular Med TRI-CON),
March 6th – 11th, San Francisco, CA, USA
Attracting over 3,300 drug discovery and development professionals from over 40 countries in 2015, the Tri Conference hosted by the Cambridge Healthtech Institute has grown into a diverse event, focusing on Molecular Medicine, specifically on Discovery, Genomics, Diagnostics and Information Technology. Dr Miguel Viribay, Vice President Sales & Marketing at SYGNIS, will present SYGNIS’ product portfolio at the Main Conference from March 7th to 9th (booth #532) and the TruePrime™ Cell-Free DNA Amplification kit, a new product currently under development in an additional symposium on Circulating Cell-free DNA on March 10th and 11th (booth #14).
More information on this conference can be found at http://www.triconference.com
10th International Symposium on Minimal Residual Cancer: Liquid Biopsy in Cancer Diagnostics and Treatment (ISMRC), March 19th - 21st, Hamburg, Germany
Organized together with the newly established EU IMI (Innovative Medicines Initiative) consortium, CANCER-ID ISMRC is a premier event focusing on the detection, characterization & clinical relevance of Circulating Tumor Cells (CTCs) in solid tumors. The 2016 program will focus on Liquid biopsy including presentations on CTCs and circulating nucleic acids (DNA, miRNA) as well as exosomes. SYGNIS will be represented by Armin Schneider (Senior Vice President Research), Ángel Picher (Associated Director Product Development) and Miguel Viribay (Vice President Sales & Marketing). The Company is currently broadening the TruePrime™ technology to empower researchers and clinicians in cancer research, cancer diagnostics, clinical drug development and patient monitoring to rapidly amplify cell free DNA from plasma and serum with highest sensitivity and reliability. Ángel Picher will present first results of this newly developed product in the poster session 3: Dissemination Biology, Circulating Nucleic Acids & Comparative Studies , on March 20, 2016, at 17:10 CET (Poster number: P113). The poster’s title is: TruePrime™ liquid biopsy: Tuning whole genome amplification towards improving the sensitivity of circulating tumor DNA analysis .
More information on ISMRC can be found at http://ismrc2016.com
About Circulating Cell-free DNA
Circulating cell-free DNA detection is currently one of the hottest topics in oncology. The fact of getting accurate and reliable results in an analysis of circulating tumor DNA in the very early stages of cancer development by non-invasive liquid biopsy opens up new fields of opportunities in both basic cancer research and cancer clinical aspects. Circulating tumor cells (CTCs) in the patient’s blood are responsible for metastases. The molecular characterization of CTCs via liquid biopsy provides a portrait of the specific disease state over time. Liquid biopsy allow for a new type of blood-based tests that have the potential to transfer cancer treatment as they allow for an easy, fast and reliable early detection of cancer and monitoring tumor progression of cancer patients under treatment. Based on the features and benefits of the TruePrime™ technology, SYGNIS is currently developing a perfect tool that significantly simplifies and standardizes amplification of cell-free DNA from liquid biopsies for these kinds of tests.
For further information please contact: SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
+34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
+49 89 210228 30
Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
SYGNIS, headquartered in Germany and Spain, specializes on the development and commercialization of innovative products for DNA amplification and sequencing. Based on its proprietary technologies, SYGNIS has developed a commercial product portfolio addressing key challenges in the fast growing fields of molecular biology and next generation sequencing applications. Key products include the TruePrime™ product line and SensiPhi®, licensed to an industry leading partner, for whole genome DNA amplification and sequencing as well as the SunScript™ Reverse Transcriptase product family to convert genetic information from RNA molecules back to DNA. SYGNIS AG is listed at the German Stock Exchange in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).